Cat Vaccine Market Report: Market Size & Forecast 2026

The global cat vaccine market encompasses preventive veterinary biologics designed to protect domestic and wild felines against infectious diseases. Market estimates for 2025 range from $1.5 billion to $2.2 billion across major research firms, with a consensus midpoint near $1.79 billion and a projected 2030 valuation of approximately $2.5 billion. The broader global veterinary vaccine market provides context, valued at roughly $10.06 billion in 2025, with feline vaccines representing a meaningful and growing segment.

• •2025 market estimates from multiple analysts range between $1.5B and $2.2B, reflecting methodological differences in scope and geography
• •Projected 2030 valuations cluster around $2.5B-$2.53B across several reports, while 2035 projections reach $3.1B-$3.5B
• •Feline vaccines represent a significant portion of the broader $10B+ global veterinary vaccine market

The market is being propelled by a combination of rising companion animal populations, growing pet humanization trends, and increasing demand for preventative veterinary care. Higher disposable incomes and greater willingness to spend on pet health have expanded vaccination coverage across both developed and emerging markets. Additionally, heightened awareness of zoonotic disease transmission has reinforced the importance of maintaining robust feline vaccination schedules.

• •Rising global cat ownership and the humanization of pets have led to increased spending on companion animal healthcare and preventive medicine
• •Growing awareness of zoonotic diseases and veterinarian-recommended core and non-core vaccine protocols drive consistent demand
• •Expanding veterinary infrastructure in emerging markets and increased pet insurance adoption further support market growth

The market is segmented by vaccine type, including core vaccines targeting feline panleukopenia, feline herpesvirus, and feline calicivirus, as well as non-core vaccines for diseases such as feline leukemia virus and chlamydophila. North America and Europe currently dominate the market due to high pet ownership rates, well-established veterinary healthcare systems, and strong regulatory frameworks. The Asia-Pacific region is expected to be the fastest-growing segment, driven by rising pet adoption, increasing veterinary clinic penetration, and growing middle-class disposable income in countries such as China, India, and Japan.

• •Core vaccines targeting panleukopenia, herpesvirus, and calicivirus form the largest segment, while non-core vaccines for feline leukemia and chlamydia represent growing categories
• •North America leads in market share due to high companion animal healthcare spending, followed by Europe with stringent vaccination guidelines
• •Asia-Pacific is projected as the fastest-growing region, fueled by rising pet adoption and expanding veterinary infrastructure in emerging economies

What are the recent trends and outlook?

The market is moving toward next-generation vaccine technologies, including recombinant and vector-based formulations that offer improved safety profiles and longer-lasting immunity without the use of live pathogens. Digital health platforms and telemedicine are beginning to influence vaccination scheduling and pet owner compliance, particularly in North America and Europe. Over the 2025-2035 forecast horizon, the market is expected to sustain a compound annual growth rate in the range of 7-9%, reaching between $3.1 billion and $3.5 billion by the end of the decade, supported by continued innovation in vaccine technology and expanding global access to veterinary care.

• •Next-generation recombinant and vector-based feline vaccines are gaining traction due to improved safety profiles and enhanced efficacy compared to traditional live-attenuated formulations
• •Telemedicine and digital health platforms are increasingly influencing vaccination compliance and scheduling, particularly in developed markets
• •Long-term projections point to a $3.1B-$3.5B market by 2030-2035, with sustained CAGR of 7-9% driven by technological innovation and expanding global veterinary access